After receiving the registration certificate, the product enters the market, and the applicant’s responsibility increases.
Why is pharmacovigilance not only a legal obligation of the marketing authorization holder? How can remarks during audits be avoided? And how does timely updating of information on the use of medicinal products improve patient safety? These and other issues were discussed at the seminar “Post-registration medicine safety surveillance: from signal monitoring to updating package leaflets.”
The training was conducted by specialists of the Center’s Pharmacovigilance Department. The following topics were discussed during the seminar:
- Signal monitoring: practiced skills in analyzing safety signals and assessing the causal relationship between the use of a medicinal product and potential risks;
- Working with databases: practiced searching for relevant medicinal product safety information, including on the websites of leading EU regulatory agencies;
- Work with reports: became familiar with approaches to working with periodic safety update reports (PSUR/PSUSA) and with the assessment of the benefit/risk balance;
- Making amendments: algorithms for preparing amendments to registration materials and package inserts were worked out.
The knowledge gained will help applicants build a reliable, proactive pharmacovigilance system. This will minimize regulatory risks for the company and contribute to improving the safety of the medical use of medicinal products in Ukraine.